AnaptysBio, Inc. (NASDAQ:ANAB) Shares Bought by Rafferty Asset Management LLC

Rafferty Asset Management LLC lifted its position in shares of AnaptysBio, Inc. (NASDAQ:ANAB - Free Report) by 83.2% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 70,883 shares of the biotechnology company's stock after acquiring an additional 32,185 shares during the quarter. Rafferty Asset Management LLC owned 0.23% of AnaptysBio worth $938,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also made changes to their positions in ANAB. JPMorgan Chase & Co. boosted its holdings in AnaptysBio by 191.4% in the 3rd quarter. JPMorgan Chase & Co. now owns 33,744 shares of the biotechnology company's stock valued at $1,130,000 after purchasing an additional 22,164 shares in the last quarter. SG Americas Securities LLC lifted its holdings in shares of AnaptysBio by 35.0% in the 4th quarter. SG Americas Securities LLC now owns 16,307 shares of the biotechnology company's stock valued at $216,000 after buying an additional 4,231 shares during the period. China Universal Asset Management Co. Ltd. boosted its stake in shares of AnaptysBio by 11.1% in the fourth quarter. China Universal Asset Management Co. Ltd. now owns 6,452 shares of the biotechnology company's stock valued at $85,000 after buying an additional 644 shares in the last quarter. Jennison Associates LLC grew its holdings in AnaptysBio by 1.6% during the fourth quarter. Jennison Associates LLC now owns 269,131 shares of the biotechnology company's stock worth $3,563,000 after acquiring an additional 4,242 shares during the period. Finally, Rhumbline Advisers grew its holdings in AnaptysBio by 3.8% during the fourth quarter. Rhumbline Advisers now owns 30,077 shares of the biotechnology company's stock worth $398,000 after acquiring an additional 1,111 shares during the period.

AnaptysBio Trading Down 1.4%

NASDAQ:ANAB opened at $20.81 on Thursday. AnaptysBio, Inc. has a twelve month low of $12.21 and a twelve month high of $41.31. The company has a market capitalization of $611.40 million, a P/E ratio of -3.42 and a beta of -0.20. The firm has a 50-day moving average price of $19.19 and a two-hundred day moving average price of $18.27.

AnaptysBio (NASDAQ:ANAB - Get Free Report) last issued its quarterly earnings data on Monday, May 5th. The biotechnology company reported ($1.28) earnings per share for the quarter, topping analysts' consensus estimates of ($1.30) by $0.02. AnaptysBio had a negative net margin of 289.75% and a negative return on equity of 287.94%. The business had revenue of $27.77 million during the quarter, compared to analysts' expectations of $15.27 million. On average, equities research analysts predict that AnaptysBio, Inc. will post -6.08 earnings per share for the current year.

AnaptysBio declared that its board has authorized a share buyback program on Monday, March 24th that authorizes the company to repurchase $75.00 million in shares. This repurchase authorization authorizes the biotechnology company to repurchase up to 13.1% of its shares through open market purchases. Shares repurchase programs are typically an indication that the company's leadership believes its stock is undervalued.

Analysts Set New Price Targets

Several brokerages have commented on ANAB. Wolfe Research initiated coverage on shares of AnaptysBio in a research report on Tuesday, February 4th. They set an "outperform" rating and a $25.00 target price on the stock. Guggenheim raised their price objective on shares of AnaptysBio from $52.00 to $54.00 and gave the company a "buy" rating in a research note on Tuesday, May 6th. Wedbush restated an "outperform" rating and set a $40.00 target price on shares of AnaptysBio in a research report on Thursday, May 1st. Wells Fargo & Company increased their target price on shares of AnaptysBio from $40.00 to $51.00 and gave the company an "overweight" rating in a report on Thursday, February 13th. Finally, HC Wainwright reissued a "neutral" rating and set a $22.00 price target on shares of AnaptysBio in a research note on Tuesday, March 4th. Four research analysts have rated the stock with a hold rating, five have assigned a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and a consensus target price of $35.88.

AnaptysBio Profile

AnaptysBio, Inc, a clinical-stage biotechnology company, focuses in delivering immunology therapeutics. Its products include Rosnilimab, an IgG1 antibody that targets PD-1+ T cells, resulting in their agonism or depletion, broadly impacting pathogenic drivers of autoimmune and inflammatory diseases; and ANB032, a non-depleting antibody that binds to the BTLA checkpoint receptor and inhibits activated T cell proliferation; ANB033, a novel anti-CD122 antagonist antibody that targets the shared common beta subunit of the receptors for IL-15 and IL-2; ANB101, a BDCA2 modulator antibody that specifically targets plasmacytoid dendritic cells (pDCs); and Imsidolimab, an antibody that inhibits the interleukin-36 receptor, which is in the Phase 3 development for the treatment of generalized pustular psoriasis.

Want to see what other hedge funds are holding ANAB? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for AnaptysBio, Inc. (NASDAQ:ANAB - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.